This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Oncology Podcasts

Episode 1

Xofigo

Why treat with Xofigo
®
(radium-223 dichloride)?

Description

Listen to experts in the field as they discuss the benefits and challenges of treatment with radium-223 dichloride and why they consider it as an option for eligible metastatic castration-resistant prostate cancer (mCRPC) patients in their clinics.

Speakers:

  • Dr Omi Parikh
     - Consultant Clinical Oncologist, Lancashire Teaching Hospitals NHS Foundation Trust
  • Ellie Cradock 
    Molecular Radiotherapy Manager, University Hospitals Bristol and Weston NHS Foundation Trust

 

This promotional podcast series has been initiated and funded by Bayer and is for healthcare professionals only.

Speakers

Prostate Cancer Podcast Episode 2
Episode 2 | Optimising patient identification and referral
Xofigo® (radium-223 dichloride)
PP-XOF-GB-0680, September 2025
Prostate Cancer Podcast Episode 3
Episode 3 | The Practicalities of Treatment
Xofigo® (radium-223 dichloride)
PP-XOF-GB-0681, September 2025

PP-XOF-GB-0679 | September 2025